Furthermore, it has been demonstrated that elevated sPD-1 levels during treatment have a more favorable outcome in NSCLC [50], whereas high amounts of PD-1 in the peripheral blood impair the treatment efficacy of anti-PD-1 in melanoma [46] and reduce survival in PDAC. The gene discussed is HOXD13; the disease is melanoma.